NeuroEM Therapeutics

NeuroEM Therapeutics is a United States medical device company based in Phoenix, Arizona, focused on the drug-free treatment of cognitive decline and neurodegenerative disease. Its core technology, Transcranial Electromagnetic Treatment leveraging Radio Frequencies (TEMT-RF), is delivered through a wearable head cap called MemorEM. According to the company, the electromagnetic waves emitted by multiple emitters in the cap disaggregate toxic protein oligomers within neurons throughout the brain, rebalance the immune system in both brain and blood, and increase the energy production of brain cells. NeuroEM states that it is the first to receive Breakthrough Device status from the FDA to treat Alzheimer's disease. The company's origin story is rooted in an unexpected laboratory finding. In 2009, neuroscientist Dr. Gary Arendash set out to test whether prolonged exposure to electromagnetic waves similar to those emitted by cellular phones would accelerate neurodegeneration in Alzheimer's mouse models. Instead, the waves prevented and even reversed cognitive impairments, breaking down amyloid-beta plaques and tau tangles while enhancing neuronal function. This discovery led Dr. Arendash to pivot from his original hypothesis and pursue a non-invasive, wearable therapeutic device for humans, and NeuroEM Therapeutics was founded to bring the technology from the lab to clinical use. NeuroEM's MemorEM device is designed to be comfortably worn on the head to administer TEMT-RF during daily in-home treatment. The company reports that its pioneering TEMT-RF technology has shown promise against Alzheimer's in all completed preclinical and clinical studies. A landmark human feasibility study in 2019 demonstrated significant cognitive improvement in Alzheimer's patients; the company cites clinical study conclusions that 87.5% of patients experienced a reversal of cognitive impairments as measured by cognitive tests and observable physiological changes, with impacts on beta-amyloid and p-tau protein levels in cerebrospinal fluid and blood plasma demonstrating that the therapy is disease-modifying. NeuroEM positions its approach as an alternative to pharmaceuticals, noting that there is no cure for Alzheimer's and that limited treatment options are often ineffective and difficult for patients. The company plans to make the MemorEM device available through neurologists and other health professionals who diagnose memory disorders once pivotal trials are completed and FDA approval is received. Its mission is to revolutionize the drug-free treatment of cognitive decline and offer hope to millions affected by neurodegenerative diseases such as Alzheimer's.

NeuroEM Therapeutics originated from an unexpected laboratory discovery. In 2009, Dr. Gary Arendash, a neuroscientist studying Alzheimer's disease, set out to test a hypothesis: that prolonged exposure to electromagnetic waves—similar to those emitted by cellular phones—would accelerate neurodegeneration in Alzheimer's mouse models. He expected to find evidence of cognitive decline and further proof of environmental risk factors for the disease. Instead, he found the exact opposite. Rather than harming the mice, the electromagnetic waves prevented and even reversed their cognitive impairments. Further analysis revealed that these waves were breaking down amyloid-beta plaques and tau tangles—the toxic proteins that drive Alzheimer's disease—while simultaneously enhancing neuronal function. This groundbreaking discovery led Dr. Arendash to pivot entirely from his original hypothesis and focus on developing a non-invasive, wearable therapeutic device capable of delivering Transcranial Electromagnetic Treatment leveraging Radio Frequencies (TEMT-RF) to humans. Recognizing the immense potential of TEMT-RF, NeuroEM Therapeutics was founded to bring this technology from the lab to real-world clinical use. Initial preclinical studies further confirmed TEMT-RF's ability to restore cognitive function, leading to a landmark human feasibility study in 2019 that demonstrated significant cognitive improvement in Alzheimer's patients. The company developed its first-in-class MemorEM device, designed to be comfortably worn on the head to administer TEMT-RF during daily in-home treatment. According to NeuroEM, the electromagnetic waves emanating from multiple emitters in the wearable head cap disaggregate toxic protein oligomers within neurons throughout the brain. Since these oligomers are increasingly believed to be the root cause of Alzheimer's disease, the company believes the MemorEM head device will directly attack the Alzheimer's disease process. TEMT-RF is described as having two additional mechanisms of action: rebalancing the immune system in both brain and blood, and increasing the energy production of brain cells. NeuroEM reports that its TEMT-RF technology has shown extraordinary promise against Alzheimer's in all completed preclinical and clinical studies. The company cites clinical study conclusions that 87.5% of patients experienced a reversal of cognitive impairments as measured by cognitive tests and observable physiological changes, and that impact on beta-amyloid and p-tau protein levels demonstrates the therapy is disease-modifying, as measured in cerebrospinal fluid (CSF) and blood plasma. Rebalanced cytokine levels are said to indicate improved immune response. NeuroEM states that it is the first to receive Breakthrough Device status from the FDA to treat Alzheimer's disease. The MemorEM device is planned to be available through neurologists and other health professionals who diagnose memory disorders once the company completes its pivotal trials and receives FDA approval. The company is based in Phoenix, Arizona, United States.

• 2019

  A landmark human feasibility study demonstrates significant cognitive improvement in Alzheimer's patients.

• 2009

  Dr. Gary Arendash begins an experiment expecting electromagnetic waves to accelerate neurodegeneration in Alzheimer's mouse models, but instead finds they prevent and reverse cognitive impairments.

• NeuroEM Therapeutics is founded to bring TEMT-RF technology from the lab to clinical use.

• NeuroEM receives Breakthrough Device status from the FDA to treat Alzheimer's disease, stated as the first to do so.

First-in-class, drug-free, non-invasive medical device therapy for Alzheimer's disease and cognitive decline, positioned as an alternative to pharmaceuticals.

• MemorEM

  A first-in-class wearable head cap device designed to comfortably administer Transcranial Electromagnetic Treatment leveraging Radio Frequencies (TEMT-RF) during daily in-home treatment.

• TEMT-RF (Transcranial Electromagnetic Treatment leveraging Radio Frequencies)

  The company's core technology, which uses electromagnetic waves from multiple emitters to disaggregate toxic protein oligomers, rebalance the immune system, and increase brain cell energy production.

1. 1NeuroEMneuroem.com
2. 2About NeuroEM Therapeutics: Innovators in Neurodegenerative Disease Treatment — NeuroEMneuroem.com
3. 3The NeuroEM Story: From Laboratory Discovery to Alzheimer's Breakthrough — NeuroEMneuroem.com
4. 4NeuroEM Therapeutics (United States)wikidata.org